Press Releases McKesson Corporation

Equities

MCK

US58155Q1031

Market Closed - Nyse Other stock markets 21:00:01 29/04/2024 BST			5-day change	1st Jan Change
536.1 ^USD	-1.33%		+1.66%	+15.79%

02:07pm	Citigroup Adjusts Price Target on McKesson to $620 From $575	MT
04-24	McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

McKesson : OJEMDA FDA Approved for Pediatric Low Grade Glioma	04-26	PU
McKesson : Ontada Names Jade Cusick Chief Commercial Officer	04-25	PU
McKesson Corporation Declares Quarterly Dividend	04-24	BU
McKesson Launches Project Oasis to Address Pharmacy Deserts in Underserved Communities	04-03	AQ
Significant Implications For FCA Defendants: Second Circuit Clarifies "Willfulness" In McKesson Decision	04-03	AQ
"Willfulness" As "Knowledge Of Illegality": Second Circuit Adopts Prevailing Federal AKS Scienter Interpretation While Reviving State FCA Claims Over Potentially Different State AKS Scienter Standards	04-02	AQ
McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date	03-27	BU
McKesson Invites Community Pharmacists to Push the Industry Forward, Together	03-15	AQ
McKesson : Barclays Global Healthcare Conference Transcript	03-14	PU
Thinking about trading options or stock in NVIDIA, Arm Holdings, Cisco Systems, McKesson, or Roku?	02-20	PR
McKesson: Fiscal Q3 Earnings Snapshot	02-07	AQ
McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance	02-07	BU
McKesson Corporation Declares Quarterly Dividend	02-01	BU
McKesson to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-09	BU
Treble Damages Require Willful, Knowing Conduct, Ninth Circuit Says	01-03	AQ
McKesson Corporation Announces Third Quarter Fiscal 2024 Earnings Release Date and Participation in January Conference	12-27	BU
McKesson : FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson	12-20	PU
McKesson : OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson	12-05	PU
TRUQAP, FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson	12-04	AQ
McKesson : TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson	12-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases McKesson Corporation

Equities

MCK

US58155Q1031

Press Releases

Filters